Patent intelligence · US
US 7947737
Method of treating hypertension and reducing serum lipase activity
Method of treating hypertension and reducing serum lipase activity
Patent details — US 7947737
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 24, 2011
- Expiration
- May 19, 2031
- Applicant
- Aker Biomarine AS
- Claims
- 5
- CPC classes
- A61K, A61K31/20
Quick answer
US 7947737 (Method of treating hypertension and reducing serum lipase activity) is held by Aker Biomarine AS. Status: granted. Granted May 24, 2011. Expires May 19, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aker Biomarine AS
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/20
More from Aker Biomarine AS
Related pharmaceutical patents in our USPTO index.
-
US 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted -
US 12331293
Bispecific antisense oligonucleotides for dystrophin exon skipping
granted -
US 12239692
Adeno-associated virus factor VIII vectors
granted -
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted -
US 12214015
Use of c-type natriuretic peptide variants to treat osteoarthritis
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12188058
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 12076372
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted
Frequently asked questions
What is US patent 7947737?
US 7947737 (Method of treating hypertension and reducing serum lipase activity) is held by Aker Biomarine AS. Status: granted. Granted May 24, 2011. Expires May 19, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7947737?
Aker Biomarine AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.
When does US 7947737 expire?
Our index shows an expiration date of May 19, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.